Halozyme Therapeutics HALO
NASDAQ HALO
$101.68 -1.30 (-1.26%)
At close: Nov 11, 2026 · 4:00 PM EST

Halozyme Therapeutics (HALO) Asset Writedowns and Impairment (2019 - 2020)

Updated

Halozyme Therapeutics' Asset Writedowns and Impairment was $48.7 million in FY2025.

Analysis

Halozyme Therapeutics (HALO) Asset Writedowns and Impairment (2019 - 2020) Analysis & Trends

  • Asset Writedowns and Impairment shows a five-year compound annual growth rate of 142.8% (FY2020 to FY2025).
  • The FY2025 figure marks the lowest annual Asset Writedowns and Impairment since FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Halozyme Therapeutics 11.73 Bn 9.97 Bn 410.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 52,000.00
Dec 31, 2019 1.13 Mn
API Access

Halozyme Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=HALO&period=max&api_key=YOUR_API_KEY